Mesoblast
MESO
29 hedge funds and large institutions have $16M invested in Mesoblast in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
45% more funds holding
Funds holding: 20 → 29 (+9)
2% more capital invested
Capital invested by funds: $15.8M → $16M (+$273K)
0.01% more ownership
Funds ownership: 0.29% → 0.29% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$268K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$254K |
| 3 |
VF
Virtu Financial
New York
|
+$163K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$150K |
| 5 |
PCM
Princeton Capital Management
Red Bank,
New Jersey
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$835K |
| 2 |
PM
Penbrook Management
New York
|
-$174K |
MESO Hedge Fund Activity: Q1 2018 in Review
29 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q1 2018, worth a combined $16M — up 1.7% from $15.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MESO positions and 1 closed out — a net gain of 9 holders — while 9 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $268K. The largest seller was Goldman Sachs, exiting entirely with an estimated $835K sold.
- 29 institutional investors held Mesoblast (MESO) as of Q1 2018, up from 20 in Q4 2017.
- Funds reported $16M of Mesoblast stock for Q1 2018, up 1.7% quarter-over-quarter.
- 10 funds opened new Mesoblast positions in Q1 2018 and 1 closed out, a net change of +9 holders.
- The largest Mesoblast buyer in Q1 2018 was Renaissance Technologies, an estimated $268K added.
- The largest Mesoblast seller in Q1 2018 was Goldman Sachs, an estimated $835K sold.
Based on aggregated 13F filings for Q1 2018.